Cutaneous Venous Malformations
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Palvella TherapeuticsWAYNE, PA
1 program1
QTORIN 3.9% rapamycin anhydrous gelPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Palvella TherapeuticsQTORIN 3.9% rapamycin anhydrous gel
Clinical Trials (1)
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Start: Dec 2024Est. completion: Mar 2026
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials
1 companies competing in this space